Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C189- Malignant neoplasm of colon, unspecified Health Condition 3: C169- Malignant neoplasm of stomach, unspecified Health Condition 4: C23- Malignant neoplasm of gallbladder Health Condition 5: C259- Malignant neoplasm of pancreas, unspecified Health Condition 6: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung Health Condition 7: C569- Malignant neoplasm of unspecifiedovary Health Cond
Conditions
Interventions
None listed
Sponsors
Govt Stanley Medical College
Eligibility
Inclusion criteria
Inclusion criteria: Cancer patients receiving dexamethasone as premedication for chemotherapy
Exclusion criteria
Exclusion criteria: Known diabetics or newly detected diabetes mellitus defined as FBS >126 mg/dL, RBS >200 mg/dL or HbA1c >6.5% at baseline testing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients who become newly detected diabetes mellitus defined as FBS more than or equal to 126 mg/dL or HbA1c more than or equal to 6.5%Timepoint: Fasting blood glucose, Post prandial blood glucose and HbA1c will be checked at 3 months and 6 months after start of dexamethasone. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting insulin levels will be studied & insulin resistance will be calculated by HOMA-IR formula. High insulin resistance will be defined by HOMA-IR more than or equal to 2.5.Timepoint: Fasting insulin levels will be studied at baseline, before start of dexamethasone & at 3 months & 6 months after starting dexamethasone.;Patient reported outcome of chemotherapy induced nausea & vomiting will be recorded using the FLIE questionnaire.Timepoint: The questionnaire will be administered at baseline, then at the beginning of every cycle for 6 to 8 cycles of chemotherapy as per patient treatment protocol.;Patients who become newly detected diabetes mellitus defined as FBS more than or equal to 126 mg/dL or HbA1c more than or equal to 6.5%Timepoint: Patients who complete their treatment & remain steroid free for 6 months after completion of treatment will undergo fasting blood glucose, post prandial blood glucose, fasting insulin level & HbA1c testing at 12 months after enrollment. | — |
Countries
India
Contacts
Public ContactRuhi Kumar
Stanley Medical College
Outcome results
None listed